RxDoctor Payments DataLook up a doctor →

Rodney Samaan, MD

Cardiovascular Disease · Mission Hills, CANPI 1578776720

Payments from drug & device makers

$1,575,971in general payments, 2019–2025

Across 729 payments — averaging $2161.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$634K
  • Alnylam Pharmaceuticals Inc.$246K
  • Applied Therapeutics, Inc.$165K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$136K
  • Novo Nordisk$78K
  • Merck$63K
  • plus $255K from 21 others
$196,533in research payments, 2019–2025

Across 20 payments — averaging $9826.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Applied Therapeutics, Inc.$145K
  • Eli Lilly$47K
  • Reddress LTD$5K

What the payments were for

  • Consulting fees$4,1942%
  • Speaking & faculty fees$172,15080%
  • Travel & lodging$27,29013%
  • Food & beverage$11,5955%
  • Education$1180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,575,971 in reported general payments places this provider in the 95th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$198,241
Medicare patients
365
Services billed
1,780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
InpefaSotagliflozin273$165,904
OzempicSemaglutide96$103,229
EliquisApixaban56$71,607
EntrestoSacubitril/Valsartan68$69,072
JardianceEmpagliflozin32$47,935
RybelsusSemaglutide26$42,005
VerquvoVericiguat31$30,817
VascepaIcosapent Ethyl52$26,349
Icosapent Ethyl94$22,495
MounjaroTirzepatide13$13,030
JanuviaSitagliptin Phosphate13$10,581
Ranolazine ErRanolazine81$7,151
SynjardyEmpagliflozin/Metformin Hcl12$6,556
Ezetimibe104$3,029
Clonidine13$2,200

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lexicon Pharmaceuticals, Inc.Inpefa$54,322$165,904273 claims
Novo NordiskOzempic, Rybelsus$77,631$145,234122 claims
PfizerEliquis$248$71,60756 claims
Boehringer IngelheimJardiance, Synjardy$472$54,49144 claims
MerckVerquvo, Januvia$63,086$41,39844 claims
Lilly USA, LLCMounjaro$389$13,03013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Mission Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →